Opendata, web and dolomites

VACCIBIOME SIGNED

Cancer Vaccines and Gut Microbiome: a rational approach to optimize cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VACCIBIOME project word cloud

Explore the words cloud of the VACCIBIOME project. It provides you a very rough idea of what is the project "VACCIBIOME" about.

patients    personalized    omics    showed    pd    light    therapeutic    combination    containing    peripheral    undergoing    predicted    mimicry    intends    processed    neo    tumor    microbiome    negatively    humans    molecular    power    normal    interplay    cd8    vaccines    select    originate    potentiators    mice    epitopes    oral    meta    tools    vaccine    effectiveness    gnotobiotic    optimize    composition    exome    first    milestone    elucidated    positively    therapy    mm    deep    models    cross    anti    criteria    immune    gut    cells    mutations    reacting    mechanisms    cell    fraction    immunotherapies    prognostic    species    formulate    microbial    transcriptome    underlying    depending    bifidobacterial    mouse    engineered    hypothesis    presented    antigens    react    goals    cocktails    gavages    lines    l1    reactive    presenting    animal    repertoire    antibody    immunotherapy    shed    antigen    discoveries    modulate    cancer    ultimate    immunity    influences    epitope    model    originates    substantially    cd4   

Project "VACCIBIOME" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI TRENTO 

Organization address
address: VIA CALEPINA 14
city: TRENTO
postcode: 38122
website: www.unitn.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 2˙450˙000 €
 EC max contribution 2˙450˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-ADG
 Funding Scheme ERC-ADG
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2024-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI TRENTO IT (TRENTO) coordinator 1˙542˙500.00
2    FONDAZIONE TOSCANA LIFE SCIENCES IT (SIENA) participant 907˙500.00

Map

 Project objective

This proposal intends to shed light on the interplay between cancer immunity and gut microbiome as a way to optimize personalized cancer vaccines and immunotherapy. The project originates from two milestone discoveries. First, to be effective cancer immunotherapies have to target CD4/CD8 T cell neo-epitopes, which originate from tumor mutations. Second, the gut microbiome influences the effectiveness of anti-PD-1/PD-L1 antibody immunotherapy both in animal models and in humans. We also recently showed in a mouse model that oral gavages with Bifidobacterial cocktails improved the therapeutic power of neo-epitope-based cancer vaccines. How microbiome affects anti-cancer immunity has not been fully elucidated yet and a deep understanding of the underlying mechanisms has the potential to substantially improve cancer immunotherapy. Since microbiome antigens are processed and presented by antigen-presenting cells and microbiome-induced T cells represent large fraction of the peripheral T cell repertoire, our hypothesis is that this large repertoire includes T cells which cross-react with cancer neo-epitopes (“molecular mimicry (MM)”). Depending upon the composition of gut microbiome, cross-reacting T cells can positively or negatively modulate anti-tumor immunity. To demonstrate the role of MM in cancer immunity this project intends (i) to select the cross-reactive T cell epitopes as predicted by meta-omics analysis of gut microbiome and exome/transcriptome analysis of cancer cell lines, (ii) to formulate vaccines containing different combination of cross-reactive epitopes, and (iii) to test vaccine anti-tumor activities in normal mice, gnotobiotic mice and mice with engineered microbiome. The ultimate goals are: 1) to provide new criteria for neo-epitope selection in personalized cancer vaccines, 2) to develop prognostic tools based on microbiome analysis, and 3) to define microbial species to be used as immune-potentiators in patients undergoing cancer therapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACCIBIOME" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACCIBIOME" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

PonD (2019)

Particles-on-Demand for Multiscale Fluid Dynamics

Read More